Andrew is Professor of Ophthalmology at the University of Southampton, Director of the Clinical Neurosciences Research Group and an Honorary Consultant Ophthalmologist at University Hospital Southampton NHS Foundation Trust.
Andrew’s scientific research is within the genetic associations of eye disease, with his clinical research focussed on AMD. He has one of the largest patient data-sets and clinical sample banks in the UK. He is the chief investigator on Roche’s Phase 3 trial of lampalizumab for dry AMD and was a co-investigator on the first clinical gene therapy trial for choroideremia. Andrew is an Observer at the Gyroscope Board of Directors.
David Kavanagh is the Professor of Complement Therapeutics at the National Renal Complement Therapeutics Centre (NRCTC). The NRCTC is a combined clinical, diagnostic and treatment centre for the complement mediated diseases: atypical haemolytic uraemic syndrome (aHUS) and C3 glomerulopathy. All patients in England treated with eculizumab for these diseases are managed through the NRCTC. His University research group has been at the forefront of defining the role of complement in renal disease and is fully integrated with the NRCTC to provide rapid translational benefits to patients. David moved to Newcastle to start his own lab in 2008 with a Wellcome Trust Fellowship following a Kidney Research UK Fellowship at the University of Edinburgh. He was previously a Fellow at Washington University School of Medicine, St. Louis. He graduated in Medicine and Immunology from the University of Glasgow in 1998 and obtained his PhD from Newcastle University in 2006. For his work defining the role of complement in aHUS, he was awarded the Renal Association’s Young Investigator (Raine) award. Additionally, he runs a glomerulonephritis and vasculitis clinic at Freeman hospital. He is chairman of the aHUS rare disease working group, an executive committee member of Complement UK.
Robert is Professor of Ophthalmology at the University of Oxford, Consultant Ophthalmologist at the Oxford Eye Hospital, Honorary Professor of Ophthalmology at the UCL Institute of Ophthalmology, Honorary Consultant Vitreoretinal Surgeon at Moorfields Eye Hospital, and the former Theme Leader for Age-related Macular Degeneration research at the Moorfields-UCL Institute of Ophthalmology Biomedical Research Centre. He is also a Fellow of the Royal College of Ophthalmologists, Fellow and former King James IV Professor of Surgery at the Royal College of Surgeons of Edinburgh and Bodley Fellow of Merton College Oxford. In 2013 he was a recipient of the international ARVO Camras Award: in 2014 the Euretina Lecture; in 2015 the Retinitis Pigmentosa Scientist of the Year Award; and in 2016 received an NIHR Senior Investigator Award. His clinical and laboratory research is dedicated to finding new treatments for blindness, particularly in patients with incurable retinal diseases, using stem cell based approaches, gene therapy and electronic devices. His laboratory developed the world’s first gene therapy treatments for choroideremia and X-linked retinitis pigmentosa – these clinical programmes are now being pursued by Nightstarx Ltd., a University of Oxford spin-out company of which he is the scientific founder.
Claire is Professor of Immunology at the University of Newcastle. Her research interests focus on complement and the mechanisms by which it drives inflammatory disease. Her recent work includes functional characterisation of complement protein variants/mutants and autoantibodies associated with diseases such as AMD, atypical haemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G). Claire’s current research is focussed on therapeutic approaches for modulation or inhibition of the complement cascade, particularly on strategies to target or ‘home’ therapy specifically to disease sites. Claire was previously Head of Complement at GlaxoSmithKline (2013-2016) and joined the University of Newcastle in 2016 to further her work in translational research; she is based within the Faculty of Medical Sciences and the National Renal Complement Therapeutics Centre.
Sir Peter Lachmann is emeritus Sheila Joan Smith Professor of Immunology at the University of Cambridge, a fellow of Christ’s College, Cambridge and honorary fellow of Trinity College, Cambridge and of Imperial College. He was knighted for service to medical science in 2002.
He has won numerous international accolades including a Gold Medal from the European Complement Network in 1997, the Medicine and Europe Senior Prize, Academie des Sciences de la Santé in 2003. His primary research interest now is the downregulation of the complement alternative pathway as a treatment for age related macular degeneration. he has previously worked on many aspects of complement biology; on microbial subversion of the innate immune response; on the immunology of measles, on systemic lupus erythematosus and on insect sting allergies.
AMD is the leading cause of irreversible blindness in the elderly and today there is no effective treatment for the atrophic form of the diseaseView More +
Gyroscope Therapeutics Ltd is developing cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement systemView More +
Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.View More +